Press Releases

DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease

December 17, 2018

DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who…

READ MORE ›

DalCor Announces the Appointment of Peter Schuepbach as Vice President of Technical Operations

December 3, 2018

DalCor today announced the appointment of Peter Schuepbach as Vice President of Technical Operations. Mr. Schuepbach will lead product development and supply chain management of dalcetrapib, currently being tested in the dal-GenE Phase 3 clinical trial.

READ MORE ›

DalCor Pharmaceuticals Announces Dr. Fouzia Laghrissi-Thode as Chief Executive Officer

April 9, 2018

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode as Chief Executive Officer, effective April 3, 2018. Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.

READ MORE ›

DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

April 5, 2018

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients. The decision for cohort expansion follows better than expected trial enrollment for dal-GenE, which has currently randomized a total of 4300 patients, an estimated 5 months ahead…

READ MORE ›

DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors

November 15, 2017

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode to its Board of Directors. Dr. Laghrissi-Thode is VicePresident at AstraZeneca. She has been leading the US Renal-Cardiology Therapeutic Area based in San Francisco and previously led the Global Cardiovascular Metabolism Therapeutic Area.

READ MORE ›

DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial — Dalcetrapib Studied in Genetically Targeted Patients with Acute Coronary Syndrome —

August 28, 2017

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into…

READ MORE ›

DalCor Pharmaceuticals to Present at Bloom Burton & Co Healthcare Investor Conference 2017

April 27, 2017

DalCor Pharmaceuticals today announced that senior management will present at the Bloom Burton & Co. Healthcare Investor Conference 2017 on Tuesday, May 2nd at 2:30 pm Eastern Time at the Sheraton Centre Toronto Hotel in Toronto, Canada.

READ MORE ›

DalCor Pharmaceuticals to Present at Needham & Co. Healthcare Conference

March 31, 2017

DalCor Pharmaceuticals today announced that senior management will participate at the 16th Needham & Co. Healthcare Conference taking place April 4-5, 2017 at the Westin Grand Central in New York. Company management will deliver a corporate presentation on Tuesday, April 4, 2017 at 10:20 a.m. ET.

READ MORE ›

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule — Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome

March 7, 2017

DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the…

READ MORE ›

DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

November 10, 2016

DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.

READ MORE ›

DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

August 23, 2016

DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. DalCor will also be assembling…

READ MORE ›

DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects of Cholesterol Efflux and Inflammation in Data

July 18, 2016

DalCor Pharmaceuticals and The Montreal Heart Institute today announced the publication in Circulation Cardiovascular Genetics of data demonstrating dalcetrapib’s genotype-dependent effects on high-sensitivity C-reactive protein (hs-CRP) from the prospective analysis of a randomized, placebo controlled clinical trial that…

READ MORE ›

DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

April 26, 2016

DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. The worldwide clinical trial will be led by the Montreal Heart Institute.

READ MORE ›

DalCor Pharmaceuticals Completes $150 Million Financing

April 19, 2016

DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically distinct population of patients with cardiovascular disease. DalCor closed a $50 million Series A financing round late in 2015 and a $100 million Series B round this week. Lead investors…

READ MORE ›

Roche to Develop Companion Diagnostic Test for Acute Coronary Syndrome

June 9, 2015

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event. The CDx test…

READ MORE ›

DalCor Pharmaceuticals Licenses a Late-Stage Investigational Cardiovascular Drug Following Major Discovery by Montreal Heart Institute (MHI) Scientists

June 8, 2015

DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine. This program is part of a major effort by DalCor and its backers,…

READ MORE ›